Corrigendum to “LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671”

Abstract

The organisers regret that in the original publication an error was introduced into the table. For the Pembro Arm the HR (95% CI) should read 0.74 (0.59-0.92) not 10.74 (0.59—0.92). The corrected table is given below.TablePembro Arm (n = 397)Placebo Arm (n = 400)EFSaMedian (95% CI), mo57.1 (38.0–NR)18.4 (14.8–22.1)5-y rate (95% CI)49.9 (44.6–55.0)26.5 (21.7–31.5)HR (95% CI)0.58 (0.48–0.69)OSMedian (95% CI), moNR (NR–NR)70.7 (53.7–NR)5-y rate (95% CI)64.6 (59.5–69.2)53.6 (48.3–58.6)HR (95% CI)0.74 (0.59–0.92)EFSa HR (95% CI)OS HR (95% CI)StagebII (n = 239)0.52 (0.35–0.76)0.67 (0.43–1.05)III (n = 558)0.58 (0.47–0.72)0.75 (0.58–0.96)PD-L1 TPSb≥50% (n = 266)0.44 (0.31–0.64)0.65 (0.42–1.00)1%–49% (n = 242)0.54 (0.39–0.75)0.67 (0.45–0.99)<1% (n = 289)0.74 (0.55–0.98)0.87 (0.62–1.21)NR, not reached; TPS, tumor proportion score.aPer investigator assessment.bAt baseline. The organisers would like to apologise for any inconvenience caused.